| 001 | 154270 | ||
| 005 | 20240229123059.0 | ||
| 024 | 7 | _ | |a 10.1016/j.bbmt.2020.03.006 |2 doi |
| 024 | 7 | _ | |a pmid:32194287 |2 pmid |
| 024 | 7 | _ | |a 1083-8791 |2 ISSN |
| 024 | 7 | _ | |a 1523-6536 |2 ISSN |
| 024 | 7 | _ | |a altmetric:77982570 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-00697 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Blocka, Joanna |b 0 |
| 245 | _ | _ | |a Response improvement rather than response status after 1st ASCT is a significant prognostic factor for survival benefit from tandem compared to single ASCT in multiple myeloma patients. |
| 260 | _ | _ | |a [S.l.] |c 2020 |b Elsevier Health Sciences |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1598860013_23423 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2020 Jul;26(7):1280-1287 |
| 520 | _ | _ | |a High-dose chemotherapy and autologous stem cell transplantation (ASCT) have been an effective treatment for newly diagnosed multiple myeloma patients for over three decades. However, it remains unclear which patients benefit from tandem compared to single ASCT. Here, we retrospectively analyzed 978 trial and non-trial patients who underwent single or tandem ASCT in Heidelberg or other German Speaking Myeloma Multicenter Group centers. Our results show that response improvement after 1st ASCT is a significant prognostic factor for progression-free survival benefit from tandem versus single ASCT (multivariable analysis p = 0.002, HR = 0.64, 95 % CI [0.48, 0.85], interaction p = 0.02). Depth of response after 1st ASCT and cytogenetic profile did not have a significant prognostic effect on survival benefit from tandem ASCT. In conclusion, our results suggest that not the response depth but rather response improvement after 1st ASCT is of prognostic significance regarding the benefit of tandem versus single ASCT. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Hielscher, Thomas |0 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |b 1 |u dkfz |
| 700 | 1 | _ | |a Goldschmidt, Hartmut |b 2 |
| 700 | 1 | _ | |a Department of Hematology and Oncology, National Center for Tumor Diseases, Heidelberg, Germany.} |b 3 |
| 700 | 1 | _ | |a Hillengass, Jens |b 4 |
| 773 | _ | _ | |a 10.1016/j.bbmt.2020.03.006 |g p. S1083879120301439 |0 PERI:(DE-600)2057605-5 |n 7 |p 1280-1287 |t Biology of blood and marrow transplantation |v 26 |y 2020 |x 1083-8791 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:154270 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b BIOL BLOOD MARROW TR : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::